TrialBritish journal of cancer2025

The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study.

Timothy A Yap et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.